علاج التهاب الكبد C المزمن بعد فشل النظام العلاجي المستند إلى السوفوسبوفير

References

DOI: 10.1093/cid/ciad319

• Generally, persons who have experienced treatment failure with a sofosbuvir-based regimen should be retreated with 12 weeks of sofosbuvir/velpatasvir/voxilaprevir.
• The exception is persons with genotype 3 infection and compensated cirrhosis for whom the addition of weight-based ribavirin to the regimen is recommended.
• Glecaprevir/pibrentasvir for 16 weeks can be used as an alternative retreatment regimen.
• SVR12, sustained virologic response 12 weeks after completion of therapy.